6-K

Ascendis Pharma A/S

Date: April 20, 2026

/s/ Michael Wolff Jensen

Michael Wolff Jensen

Executive Vice President, Chief Legal Officer

6-K 1 d620541d6k.htm 6-K 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April, 2026

Commission File Number: 001-36815

Ascendis Pharma A/S

(Translation of registrant’s name into English)

Tuborg Boulevard 12

DK-2900 Hellerup

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-228576, 333-254101, 333-261550, 333-270088, 333-277519, 333-281916, 333-285322 and 333-293854) and Form F-3 (Registration Numbers 333-209336 and 333-282196) of Ascendis Pharma A/S (the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

On April 20, 2026, the Company announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market (“Nasdaq”), replacing the listing of American Depositary Shares (“ADSs”).

The ordinary shares trade under the same ticker symbol “ASND” as previously used for the ADS listing. The ordinary shares trade under CUSIP number K08588103 and ISIN DK0060606333.

On April 8, 2026, the Company announced plans to mandatorily exchange all outstanding ADSs for ordinary shares, with each ADS exchangeable for one ordinary share listed on Nasdaq. The last trading day for ADSs on Nasdaq was April 17, 2026. As of April 20, 2026, all outstanding ADSs were exchanged for ordinary shares.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SEC Form 6-K filed by Ascendis Pharma A/S